HRAS and uterine carcinoma: RAS mutations are acknowledged pathogenic genomic alterations in sebaceous nevus, which are preserved in secondary tumors, and more specifically, HRAS G13R has been described in apocrine carcinoma and is consistent with PCAC diagnosis arising from a sebaceous nevus in this report [15]. FBXW7 is among the family of F-box proteins that are involved in the ubiquitination and destruction through the proteasome degradation of oncoproteins and about the FBXW7 Y545C missense mutation in breast invasive ductal carcinoma, head and neck squamous carcinoma, and uterine carcinoma.